Aclaris Therapts (ACRS)

$4.20 +0.06 (1.45%)
Market Cap 506.50M
Revenue (ttm) 7.83M
Net Income (ttm) -64.92M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -829.12%
Debt to Equity Ratio 0.00
Volume 940,000
Avg Vol 1,956,192
Day's Range N/A - N/A
Shares Out 120.60M
Stochastic %K 98%
Beta 0.67
Analysts Strong Sell
Price Target $8.29

Company Profile

Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering and developing novel molecule product candidates for immuno-inflammatory diseases in the United States. The company product pipeline includes Bosakitug (ATI-045), an anti-thymic stromal lymphopoietin monoclonal antibody in Phase 2 trial to treat moderate to severe atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and moderate to severe chronic obstructive pulmonary disease; ATI-2...

Industry: Biotechnology
Sector: Healthcare
Phone: 484 324 7933
Address:
701 Lee Road, Suite 103, Wayne, United States
Acan1219
Acan1219 Apr. 2 at 7:07 PM
$ACRS Marching up ⬆️ in April…. Get it my Bull’s!! 😎🏦🏦
0 · Reply
buymoremakemore
buymoremakemore Apr. 2 at 6:57 PM
$ACRS $4.20
0 · Reply
Acan1219
Acan1219 Apr. 2 at 3:13 PM
$ACRS Higher Highs my Bull’s!! Let’s Goooo!!💰💰💰
0 · Reply
dibatista
dibatista Apr. 1 at 3:57 PM
$ACRS Luv u
0 · Reply
Acan1219
Acan1219 Apr. 1 at 1:43 PM
$ACRS 4’s today my Bull’s!! On our way to $16.00
0 · Reply
dibatista
dibatista Mar. 31 at 8:19 PM
$ACRS SKY
0 · Reply
buymoremakemore
buymoremakemore Mar. 27 at 8:00 PM
$ACRS Added 5,000 more shares today
0 · Reply
Acan1219
Acan1219 Mar. 25 at 10:47 PM
$ACRS All aboard!! Last chance to get in before we rocket through the $4’s on our way to $16.00 Big Money Investors Just Loaded up Millions of SH’s!! Let’s Gooo my Bull’s!! 💰💰💰
0 · Reply
dibatista
dibatista Mar. 25 at 8:31 PM
$ACRS is back!
0 · Reply
OriginalTradeonrumor
OriginalTradeonrumor Mar. 25 at 5:45 AM
$ACRS I’m back in …in the 3.20’s
0 · Reply
Latest News on ACRS
Results Presented at 2026 American Academy of Dermatology (AAD) Annual Meeting Provide Additional Support for the Therapeutic Potential of ATI-2138

Mar 27, 2026, 10:10 AM EDT - 9 days ago

Results Presented at 2026 American Academy of Dermatology (AAD) Annual Meeting Provide Additional Support for the Therapeutic Potential of ATI-2138

Aclaris Therapeutics Announces Poster on Results from Phase 2a Trial of ATI-2138 at the 2026 American Academy of Dermatology (AAD) Annual Meeting

Mar 20, 2026, 11:00 AM EDT - 16 days ago

Aclaris Therapeutics Announces Poster on Results from Phase 2a Trial of ATI-2138 at the 2026 American Academy of Dermatology (AAD) Annual Meeting

Aclaris Therapeutics Completes Enrollment in Phase 2 Trial of Bosakitug (ATI-045) in Atopic Dermatitis

Mar 18, 2026, 6:55 AM EDT - 18 days ago

Aclaris Therapeutics Completes Enrollment in Phase 2 Trial of Bosakitug (ATI-045) in Atopic Dermatitis

Aclaris Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Feb 26, 2026, 6:58 AM EST - 5 weeks ago

Aclaris Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Aclaris Therapeutics Initiates Phase 1b Proof-of-Concept Trial in Patients with Asthma with its Novel Bispecific Anti-TSLP/IL-4Rα Antibody ATI-052

Feb 24, 2026, 7:00 AM EST - 5 weeks ago

Aclaris Therapeutics Initiates Phase 1b Proof-of-Concept Trial in Patients with Asthma with its Novel Bispecific Anti-TSLP/IL-4Rα Antibody ATI-052

Aclaris Therapeutics' Novel ITK/JAK3 Inhibitor ATI-2138 Demonstrates Rapid and Sustained Hair Regrowth in Validated Murine Model of Alopecia Areata (AA)

Jan 27, 2026, 6:55 AM EST - 2 months ago

Aclaris Therapeutics' Novel ITK/JAK3 Inhibitor ATI-2138 Demonstrates Rapid and Sustained Hair Regrowth in Validated Murine Model of Alopecia Areata (AA)

Aclaris Therapeutics Initiates Phase 1b Proof-of-Concept Trial in Atopic Dermatitis (AD) with Its Novel Bispecific Antibody ATI-052

Jan 12, 2026, 6:55 AM EST - 2 months ago

Aclaris Therapeutics Initiates Phase 1b Proof-of-Concept Trial in Atopic Dermatitis (AD) with Its Novel Bispecific Antibody ATI-052

Aclaris Therapeutics, Inc. (ACRS) Discusses Positive Interim Results From ATI-052 Phase 1a Trial and Potential Therapeutic Advantages Transcript

Jan 6, 2026, 3:58 PM EST - 3 months ago

Aclaris Therapeutics, Inc. (ACRS) Discusses Positive Interim Results From ATI-052 Phase 1a Trial and Potential Therapeutic Advantages Transcript

Aclaris Therapeutics Announces Positive Interim Results of Phase 1a Trial of Anti-TSLP/IL-4Rα Bispecific Antibody ATI-052 Supporting Expedited Clinical Development

Jan 6, 2026, 6:59 AM EST - 3 months ago

Aclaris Therapeutics Announces Positive Interim Results of Phase 1a Trial of Anti-TSLP/IL-4Rα Bispecific Antibody ATI-052 Supporting Expedited Clinical Development

Aclaris Therapeutics Added to the NASDAQ Biotechnology Index (NBI)

Dec 19, 2025, 4:01 PM EST - 3 months ago

Aclaris Therapeutics Added to the NASDAQ Biotechnology Index (NBI)

Aclaris Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference

Nov 25, 2025, 8:00 AM EST - 4 months ago

Aclaris Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference

Aclaris Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Nov 6, 2025, 6:59 AM EST - 5 months ago

Aclaris Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Aclaris Therapeutics to Participate in Three November Healthcare Conferences

Oct 29, 2025, 7:30 AM EDT - 5 months ago

Aclaris Therapeutics to Participate in Three November Healthcare Conferences

Aclaris Therapeutics, Inc. - Special Call

Oct 14, 2025, 5:46 PM EDT - 6 months ago

Aclaris Therapeutics, Inc. - Special Call

Aclaris Therapeutics to Host In-Person and Webcast R&D Day, “Patient Focused Innovation: Addressing Gaps in Immuno-Inflammatory Markets”, in New York on October 14, 2025

Sep 30, 2025, 7:00 AM EDT - 6 months ago

Aclaris Therapeutics to Host In-Person and Webcast R&D Day, “Patient Focused Innovation: Addressing Gaps in Immuno-Inflammatory Markets”, in New York on October 14, 2025

Aclaris Therapeutics Announces Late-Breaking Abstract and Oral Presentation On ATI-2138 Phase 2a Results at the 2025 European Academy of Dermatology and Venereology (EADV) Congress

Sep 9, 2025, 7:00 AM EDT - 7 months ago

Aclaris Therapeutics Announces Late-Breaking Abstract and Oral Presentation On ATI-2138 Phase 2a Results at the 2025 European Academy of Dermatology and Venereology (EADV) Congress

Aclaris Therapeutics to Participate in Two September Healthcare Conferences

Aug 27, 2025, 8:00 AM EDT - 7 months ago

Aclaris Therapeutics to Participate in Two September Healthcare Conferences

Aclaris Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 7, 2025, 6:59 AM EDT - 8 months ago

Aclaris Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aclaris Therapeutics Announces Positive Top-Line Results from Open-Label Phase 2a Trial of ATI-2138, a Potent and Selective Investigational Inhibitor of ITK and JAK3; Trial Achieves Primary and Key Secondary Endpoints

Jul 29, 2025, 4:01 PM EDT - 8 months ago

Aclaris Therapeutics Announces Positive Top-Line Results from Open-Label Phase 2a Trial of ATI-2138, a Potent and Selective Investigational Inhibitor of ITK and JAK3; Trial Achieves Primary and Key Secondary Endpoints

Aclaris Therapeutics Announces Leadership Transition

Jul 28, 2025, 8:45 AM EDT - 8 months ago

Aclaris Therapeutics Announces Leadership Transition

Aclaris Therapeutics Added to the Russell 2000® and Russell 3000® Indexes

Jun 30, 2025, 9:31 AM EDT - 9 months ago

Aclaris Therapeutics Added to the Russell 2000® and Russell 3000® Indexes

Aclaris Therapeutics to Participate in the H.C. Wainwright Inflammation & Immunology Virtual Conference

Jun 26, 2025, 4:01 PM EDT - 10 months ago

Aclaris Therapeutics to Participate in the H.C. Wainwright Inflammation & Immunology Virtual Conference

Aclaris Therapeutics Initiates Phase 1a/1b Program for its Novel Bispecific Antibody ATI-052

Jun 23, 2025, 6:59 AM EDT - 10 months ago

Aclaris Therapeutics Initiates Phase 1a/1b Program for its Novel Bispecific Antibody ATI-052

Aclaris Therapeutics to Participate in Two June Healthcare Conferences

May 28, 2025, 9:20 AM EDT - 11 months ago

Aclaris Therapeutics to Participate in Two June Healthcare Conferences

Aclaris Therapeutics to Participate in the HC Wainwright “HCW@Home” Series

May 9, 2025, 7:00 AM EDT - 11 months ago

Aclaris Therapeutics to Participate in the HC Wainwright “HCW@Home” Series

Aclaris Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 8, 2025, 6:50 AM EDT - 11 months ago

Aclaris Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

Aclaris Therapeutics Appoints Jesse Hall, M.D. as Chief Medical Officer

Apr 29, 2025, 7:00 AM EDT - 1 year ago

Aclaris Therapeutics Appoints Jesse Hall, M.D. as Chief Medical Officer

Aclaris Therapeutics to Participate in Two March Healthcare Conferences

Mar 4, 2025, 7:00 AM EST - 1 year ago

Aclaris Therapeutics to Participate in Two March Healthcare Conferences

New Publication Highlights Unique Properties of ATI-2138, a Potent and Selective Inhibitor of ITK and JAK3

Feb 12, 2025, 6:50 AM EST - 1 year ago

New Publication Highlights Unique Properties of ATI-2138, a Potent and Selective Inhibitor of ITK and JAK3

Aclaris Therapeutics Announces Formation of New Scientific Advisory Board

Jan 30, 2025, 4:01 PM EST - 1 year ago

Aclaris Therapeutics Announces Formation of New Scientific Advisory Board

Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Jan 6, 2025, 4:30 PM EST - 1 year ago

Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Aclaris Stock Rises As Analyst Projects Billions In Sales For New Therapy

Dec 23, 2024, 1:41 PM EST - 1 year ago

Aclaris Stock Rises As Analyst Projects Billions In Sales For New Therapy

Aclaris Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference

Nov 26, 2024, 4:30 PM EST - 1 year ago

Aclaris Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference

Aclaris Stock Soars As Analysts See Fresh Momentum After Strategic Review And Encouraging Promising Pipeline Developments

Nov 19, 2024, 3:27 PM EST - 1 year ago

Aclaris Stock Soars As Analysts See Fresh Momentum After Strategic Review And Encouraging Promising Pipeline Developments

Biosion Announces Exclusive, Global License Agreement with Aclaris Therapeutics on two potential First-in-Class and Best-in-Class Immunology Assets

Nov 18, 2024, 8:50 AM EST - 1 year ago

Biosion Announces Exclusive, Global License Agreement with Aclaris Therapeutics on two potential First-in-Class and Best-in-Class Immunology Assets

Aclaris Therapeutics Announces Exclusive, Global License Agreement with Biosion, Inc., adding Potential Best-in-Class Biologics Assets to Pipeline

Nov 18, 2024, 8:10 AM EST - 1 year ago

Aclaris Therapeutics Announces Exclusive, Global License Agreement with Biosion, Inc., adding Potential Best-in-Class Biologics Assets to Pipeline

Aclaris Therapeutics Announces $80 Million Private Placement

Nov 18, 2024, 8:10 AM EST - 1 year ago

Aclaris Therapeutics Announces $80 Million Private Placement

Aclaris Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of ATI-2138, an Investigational Oral Covalent ITK/JAK3 Inhibitor for the Treatment of Moderate to Severe Atopic Dermatitis

Sep 17, 2024, 7:00 AM EDT - 1 year ago

Aclaris Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of ATI-2138, an Investigational Oral Covalent ITK/JAK3 Inhibitor for the Treatment of Moderate to Severe Atopic Dermatitis

Aclaris Therapeutics to Participate in the 2024 Cantor Global Healthcare Conference

Sep 10, 2024, 7:00 AM EDT - 1 year ago

Aclaris Therapeutics to Participate in the 2024 Cantor Global Healthcare Conference

Aclaris Therapeutics Announces Sale of OLUMIANT® Royalties and Milestones to OMERS Life Sciences for Up to $31.5 Million

Jul 16, 2024, 4:01 PM EDT - 1 year ago

Aclaris Therapeutics Announces Sale of OLUMIANT® Royalties and Milestones to OMERS Life Sciences for Up to $31.5 Million

Rheumatoid Arthritis Market and Epidemiology Forecast 2024-2034 Featuring Analysis of ATI-450 (Aclaris Therapeutics) and Olumiant/Baricitinib (Eli Lilly/Incyte)

Jun 25, 2024, 12:36 PM EDT - 1 year ago

Rheumatoid Arthritis Market and Epidemiology Forecast 2024-2034 Featuring Analysis of ATI-450 (Aclaris Therapeutics) and Olumiant/Baricitinib (Eli Lilly/Incyte)

Aclaris Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

Jun 6, 2024, 7:00 AM EDT - 1 year ago

Aclaris Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

American Clinical Research Services Announces Strategic Acquisition of Elixia

May 8, 2024, 6:30 AM EDT - 2 years ago

American Clinical Research Services Announces Strategic Acquisition of Elixia

Aclaris Therapeutics, Inc. (ACRS) Q1 2024 Earnings Call Transcript

May 7, 2024, 9:44 PM EDT - 2 years ago

Aclaris Therapeutics, Inc. (ACRS) Q1 2024 Earnings Call Transcript

Aclaris Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update

May 7, 2024, 4:01 PM EDT - 2 years ago

Aclaris Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update

Flare Therapeutics Appoints Douglas Manion, M.D., FRCP (C) as Chief Executive Officer

Apr 23, 2024, 8:00 AM EDT - 2 years ago

Flare Therapeutics Appoints Douglas Manion, M.D., FRCP (C) as Chief Executive Officer

Aclaris Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update

Feb 27, 2024, 7:00 AM EST - 2 years ago

Aclaris Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update

Aclaris Therapeutics Announces Top-line Results from 4-Week Phase 2b Trial of ATI-1777 for Mild to Severe Atopic Dermatitis

Jan 10, 2024, 7:00 AM EST - 2 years ago

Aclaris Therapeutics Announces Top-line Results from 4-Week Phase 2b Trial of ATI-1777 for Mild to Severe Atopic Dermatitis

Aclaris Therapeutics Provides Corporate Update

Dec 19, 2023, 4:01 PM EST - 2 years ago

Aclaris Therapeutics Provides Corporate Update

Aclaris Therapeutics Announces Patent License Agreement with Sun Pharma for Alopecia

Dec 5, 2023, 4:01 PM EST - 2 years ago

Aclaris Therapeutics Announces Patent License Agreement with Sun Pharma for Alopecia

Acan1219
Acan1219 Apr. 2 at 7:07 PM
$ACRS Marching up ⬆️ in April…. Get it my Bull’s!! 😎🏦🏦
0 · Reply
buymoremakemore
buymoremakemore Apr. 2 at 6:57 PM
$ACRS $4.20
0 · Reply
Acan1219
Acan1219 Apr. 2 at 3:13 PM
$ACRS Higher Highs my Bull’s!! Let’s Goooo!!💰💰💰
0 · Reply
dibatista
dibatista Apr. 1 at 3:57 PM
$ACRS Luv u
0 · Reply
Acan1219
Acan1219 Apr. 1 at 1:43 PM
$ACRS 4’s today my Bull’s!! On our way to $16.00
0 · Reply
dibatista
dibatista Mar. 31 at 8:19 PM
$ACRS SKY
0 · Reply
buymoremakemore
buymoremakemore Mar. 27 at 8:00 PM
$ACRS Added 5,000 more shares today
0 · Reply
Acan1219
Acan1219 Mar. 25 at 10:47 PM
$ACRS All aboard!! Last chance to get in before we rocket through the $4’s on our way to $16.00 Big Money Investors Just Loaded up Millions of SH’s!! Let’s Gooo my Bull’s!! 💰💰💰
0 · Reply
dibatista
dibatista Mar. 25 at 8:31 PM
$ACRS is back!
0 · Reply
OriginalTradeonrumor
OriginalTradeonrumor Mar. 25 at 5:45 AM
$ACRS I’m back in …in the 3.20’s
0 · Reply
Acan1219
Acan1219 Mar. 24 at 6:48 PM
$ACRS 🤣🤣🤣 What a Loser!! The $1’s are just around the corner!!🤣🤣🤣
0 · Reply
JDVeritone1
JDVeritone1 Mar. 24 at 6:34 PM
$ACRS why is this dirtbag trolling our board with nonsense and bragging about this pile of anal cum?
0 · Reply
buymoremakemore
buymoremakemore Mar. 24 at 5:38 PM
$ACRS Bio is getting pummeled today. Wouldnt surprise me if ACRS is going to track a bit with CRVS now. We should be rooting for CRVS since we both make up the ITK space.
0 · Reply
Sheriff87
Sheriff87 Mar. 24 at 5:32 PM
$ACRS oh damn :(
0 · Reply
JDVeritone1
JDVeritone1 Mar. 24 at 5:10 PM
$ACRS you dirty troll, your stock is garbage.
0 · Reply
JDVeritone1
JDVeritone1 Mar. 23 at 7:31 PM
$ACRS where's your umbrella?
0 · Reply
JDVeritone1
JDVeritone1 Mar. 20 at 9:51 PM
$ACRS 100?? Lol, you're a few zeros off.
1 · Reply
JDVeritone1
JDVeritone1 Mar. 20 at 9:49 PM
$ACRS You typed too soon, you finished red. No I think I'll stay with a company that's shown growth the last 2 quarters and will continue. I can't wait until ACRS earnings come out!!!!
0 · Reply
Acan1219
Acan1219 Mar. 20 at 8:56 PM
$ACRS If you didn’t lose all your money of your 100 SH’s of VERI you could’ve bought a Real Stock ACRS that’s on it’s Climb Up ⬆️ to Double Digits and made Bank 🏦 Now Beat it!
0 · Reply
JDVeritone1
JDVeritone1 Mar. 20 at 8:23 PM
$ACRS long-term dog
0 · Reply
Acan1219
Acan1219 Mar. 19 at 2:42 PM
$ACRS Only one Green!! Let’s Gooo my Bull’s!!
0 · Reply
JoeTheMiner
JoeTheMiner Mar. 18 at 10:25 PM
$ACRS 💩💩💩💩💩💩
0 · Reply